ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

27.20
0.10 0.37
OTC
Prev Close 27.30
Open 27.11
Day Low/High 27.02 / 27.29
52 Wk Low/High 27.06 / 35.13
Volume 1.55M
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 177.38B
Div & Yield N.A. (N.A)

Latest News

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

In a few weeks, investors will know if Lilly's solanezumab is a groundbreaking treatment for Alzheimer's or another drug casualty to a disease that has eluded pharmaceutical companies for years.

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in people with GCA.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Roche Launches New RNA HyperPrep Product Line

Roche Launches New RNA HyperPrep Product Line

A streamlined solution for the preparation of high-quality RNA-sequencing libraries

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society...

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from Actemra ® (tocilizumab) and Rituxan ® (rituximab) will be presented during the 2016 American College of...

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

First FDA-approved test to support patient treatment decisions for TECENTRIQ (atezolizumab) in non-small cell lung cancer

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

First high-throughput molecular platform approved for CLIA moderately complex testing expected to enhance quality, streamline workflow and better utilize staff

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Next generation cobas® MPX assay now approved for donor screening applications in the United States

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.

FDA Approves Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) For People With A Specific Type Of Metastatic Lung Cancer

FDA Approves Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) For People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) Prefilled Syringe

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) Prefilled Syringe

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Priority Review To Genentech's Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application For Myopic Choroidal Neovascularization

FDA Grants Priority Review To Genentech's Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application For Myopic Choroidal Neovascularization

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared To Chemotherapy Regardless Of PD-L1 Status In A Specific Type Of Lung Cancer In Phase III Study

Genentech's TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared To Chemotherapy Regardless Of PD-L1 Status In A Specific Type Of Lung Cancer In Phase III Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III OAK study of TECENTRIQ ® (atezolizumab) at the European Society of Medical Oncology (ESMO)...

FDA Grants Breakthrough Therapy Designation For Genentech's Actemra® (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Breakthrough Therapy Designation For Genentech's Actemra® (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Breakthrough Therapy Designation For Genentech's Alecensa® (Alectinib) For First-Line Treatment Of People With ALK-Positive NSCLC

FDA Grants Breakthrough Therapy Designation For Genentech's Alecensa® (Alectinib) For First-Line Treatment Of People With ALK-Positive NSCLC

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has received a second Breakthrough Therapy Designation (BTD) from the U.

Harmony® Prenatal Test For Assessment Of Down Syndrome And Other Chromosomal Disorders Receives CE Mark

Harmony® Prenatal Test For Assessment Of Down Syndrome And Other Chromosomal Disorders Receives CE Mark

Laboratories, healthcare providers, and expectant parents receive greater access to the non-invasive prenatal test

FDA Grants Roche Label Extension For The Cobas® EGFR Mutation Test V2 For Use With Plasma As A Companion Diagnostic For TAGRISSO™

FDA Grants Roche Label Extension For The Cobas® EGFR Mutation Test V2 For Use With Plasma As A Companion Diagnostic For TAGRISSO™

Test utilizes either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapies

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy

A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive...

2 Hot Biotech Stocks Trading at Bargain Prices Right Now

2 Hot Biotech Stocks Trading at Bargain Prices Right Now

In the rising biotech sector, it's hard to find solid growth stocks that are also cheap. But we've done the homework for you.

How to Cash in on the Fight Against the Zika Virus

How to Cash in on the Fight Against the Zika Virus

Where some see danger and upheaval, investors see opportunity. And the harrowing Zika virus is no different. Investors are jumping into stocks focused on detecting or wiping out the virus.